Toggle Sidebar
Tracking
The Digest
Dashboard
Changes
Readouts
Trials
Companies
Comparisons
Automation
Nightly sweep
Settings
Tracker
↳
Sign in
Sign in
Explore the registry
Track Lorlatinib's trials
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Lorlatinib
Ongoing
Active not recruiting
Phase 3
Open NCT03052608 on ClinicalTrials.gov ↗
Population
Loading…
Intervention
Loading…
Comparator
Loading…
Outcomes
Loading…
Overview
Endpoints
Eligibility
Full record
